Eli Lilly And Company · NYSE:LLY
Eli Lilly And — Bear Stearns Health Care Conference 2006
14 slides from Eli Lilly And's conference presentation, Sep 12, 2006
Slide 1: Dr. Steven M. Paul, Bear Stearns Health Care Conference
Dr. Steven M. Paul President, Lilly Research Laboratories Bear Stearns Health Care Conference September 12th, 2006
Slide 2: SEC Disclosure
SEC Disclosure During this presentation, we anticipate making projections and forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. For example, our results may be affected by competitive developments, the tim
Slide 3: Lilly Strengths
Lilly Strengths • Strategy of independence, innovation and partnering • Nearly tripled portfolio of innovative products • Excellent R&D throughput • Strong reputation as a partner • Aggressively pursuing productivity improvements • No major patent expirations until 2011 • Pursuing “tailored therapeu
Slide 4: Lilly Priorities
Lilly Priorities • Grow sales of expanded portfolio • Deliver late-stage molecules, continuously replenish pipeline • Increase productivity across the value chain - accelerating earnings growth
Slide 5: Lilly Productivity
Lilly Productivity Key Initiatives • Prolific use of biomarkers in early development • Six sigma projects focused on reducing cost & cycle times • Sourcing global talent to increase flexibility & productivity • Leveraging expertise in biotech products • Leveraging synergies across therapeutic areas
Slide 6: Lilly's Rapidly Expanding Portfolio of Launched Products
Lilly’s Rapidly Expanding Portfolio Osteoporosis/ Acute Care/ CNS Diabetes Care Oncology Primary Care Specialty Zyprexa Evista Humulin Humatrope Gemzar Launched Products 1998 1982 1987 1995 1996 Strattera Forteo Humalog ReoPro Alimta 1996 1995 2004 2003 2002 Actos Xigris Symbyax Cialis* 2001 2004 20
Slide 7: Byetta
Byetta First-in-class Incretin Mimetic • Approved in US for type 2 diabetes as adjunct to metformin and/or sulfonylurea • Have submitted an sNDA for combination use with TZDs • LAR formulation in development - once-weekly injection for type 2 diabetes • Preliminary results of phase 2 LAR study • A1C
Slide 8: Inhaled Insulin
Inhaled Insulin Promising Formulation and Device • Earlier insulin treatment may improve glucose control • We believe patients will prefer a simple system • Phase 2 results: • Inhaled system provided HbA1C control similar to injectable insulin • 80% of patients preferred inhaled system to meal-time
Slide 9: Prasugrel
Prasugrel Acute Coronary Syndromes • Co-developing & co-commercializing with Sankyo • Platelet aggregation inhibitor • Initial submission for acute coronary syndromes (ACS) • Phase 1 studies suggest prasugrel may have superior profile • Greater inhibition of platelet aggregation (IPA) • Faster onset
Slide 10: Enzastaurin and Beyond
Enzastaurin and Beyond Enzastaurin • Glioblastoma • Glioblastoma pivotal study begun Q1 2006 • U.S. submission anticipated in 2008 • Non-Hodgkin’s Lymphoma (diffuse large B-cell lymphoma) • Pivotal study in earlier stage of NHL begun Q2 2006 Survivin ASO with ISIS • Positive pre-clinical results • P
Slide 11: Arzoxifene
Arzoxifene Selective Estrogen Receptor Modulator (SERM) • Designed for higher potency & bioavailability • Potential benefits for patients: • Vertebral and non-vertebral fracture efficacy • Breast cancer risk reduction • Two pivotal registration studies fully enrolled • Osteoporosis prevention and ut
Slide 12: Lilly Neuroscience
Lilly Neuroscience • Research focus: • Neurology: Alzheimer’s, Parkinson’s, migraine, pain • Psychiatric: anxiety, schizophrenia, insomnia, cognition • Pruvanserin (5HT2A receptor antagonist) for insomnia • Study of sleep quality & architecture • Phase 2 safety and efficacy work on going • Gamma sec
Slide 13: Conclusion
Eli Lilly and Company Conclusion Priorities: • Grow sales of expanded portfolio • Deliver late-stage molecules, continuously replenish pipeline • Increase productivity across the value chain - accelerating earnings growth
Slide 14: Answers That Matter.
Lilly Answers That Matter.
Eli Lilly and Company — Bear Stearns Health Care Conference 2006 on 6ix